Clinical trial
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or…
NCT00409565 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00409565 |
|---|---|
| Title | A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer |
| Official title | A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Squamous Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Cetuximab, Bevacizumab |
| Enrollment | 48 |
| Start date | Sep 1, 2006 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Dec 11, 2006 |
| Last update posted | Oct 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: